covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Concentraciones de hemoglobina glucosilada A1c, lipoproteínas de baja densidad ...
Información de la revista
Vol. 53. Núm. 4.
Páginas 246-251 (abril 2006)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 53. Núm. 4.
Páginas 246-251 (abril 2006)
Originales
Acceso a texto completo
Concentraciones de hemoglobina glucosilada A1c, lipoproteínas de baja densidad y valores de presión arterial en adultos diagnosticados previamente de diabetes mellitus tipo 2
Glycosylated hemoglobin A1c, low-density lipoproteins and blood pressure among adults with previously diagnosed diabetes
Visitas
7095
M. Taglea,
Autor para correspondencia
mtagle@gye.satnet.net

Correspondencia: Dr. M. Tagle. Casilla postal 09-01-3383 Guayaquil. Ecuador.
, F. Gómezb, A. Taglec,d, C. Lópeza, W. Garciaa
a Posgrado de Endocrinología. Escuela de Graduados. Facultad de Ciencias Médicas. Universidad de Guayaquil. Guayaquil. Ecuador
b Dispensario N.° 6. Instituto Ecuatoriano de Seguridad Social (IESS). Guayaquil. Ecuador
c Facultad de Ciencias Médicas. Universidad Católica de Guayaquil. Guayaquil. Ecuador
d Servicio de Endocrinología del Hospital Teodoro Maldonado Carbo. Instituto Ecuatoriano de Seguridad Social. Guayaquil. Ecuador
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Objetivo

Evaluar el grado de control de los factores de riesgo para enfermedad vascular en adultos diagnosticados previamente de diabetes mellitus tipo 2 (DM2), que acuden de manera regular a la consulta ambulatoria de endocrinología.

Material y método

Analizamos los datos de una encuesta conducida durante el año 2004 en 129 sujetos diagnosticados previamente de DM2. Los participantes eran adultos entre 20 y 80 años y participaron tanto en la entrevista como en el examen. Los principales parámetros medidos fueron las concentraciones de hemoglobina glucosilada A1c (HbA1c), el colesterol ligado a lipoproteínas de baja densidad (cLDL) y los valores de presión arterial (PA) en referencia a los objetivos establecidos para personas con diabetes por la Asociación Americana de Diabetes (ADA). Se utilizó el promedio de un mínimo de 3 valores obtenidos a lo largo del año.

Resultados

El 20,2% de los participantes alcanzó el objetivo para HbA1c<7% (un 19,6% en varones y un 20,5% en mujeres) y el 24,8% de los participantes tuvieron HbA1c<8% (un 17,6% en varones y un 29,5% en mujeres), concentración por encima de los valores de HbA1c que recomiendan emprender acciones. Sólo el 7,8% de los participantes alcanzó concentraciones de cLDL<100 mg/dl (un 9,8% en varones y un 6,4% en mujeres). El 45,7% de los participantes logró el objetivo de presión arterial sistólica (PAS)<130 mmHg y diastólica (PAD)<80 mmHg (un 51% en varones y un 42,3% en mujeres) y el 31,8% (un 31,4% en varones y un 32,1% en mujeres) tienen hipertensión (PAS140 o PAD80mmHg). Sólo el 1,6% de los adultos con DM consiguieron los 3 objetivos recomendados para HbA1c<7%, PA<130/80mmHg y cLDL<100mg/dl.

Conclusiones

Son necesarios esfuerzos más enérgicos en el campo de la salud pública para el control de los factores de riesgo para enfermedad vascular en individuos con DM diagnosticada.

Palabras clave:
Diabetes mellitus tipo 2
Objetivos de control metabólico
HbA1c
cLDL
Presión arterial
Objective

To evaluate the degree of control of risk factors for vascular disease in adults with previously diagnosed type 2 diabetes (DM2) undergoing regular ambulatory evaluation in an endocrinology department.

Material and method

We analyzed data from a survey conducted in 2004 in 129 adults with previously diagnosed DM2. Participants were adults aged 20 years old and older who participated in both the interview and examination. Main outcome measures: values of glycosylated hemoglobin (HbA1c), lowdensity lipoprotein (cLDL) and blood pressure with reference to the target goals for persons with diabetes established by the American Diabetes Association. The means of a minimum of three values obtained throughout the year were used.

Results

Only 20.2% of participants achieved the target goal of HbA1c level lower than 7.0% (19.6% in men and 20.5% in women) and 24.8% of participants were above the recommended “take action” HbA1c level of more than 8.0%. Only 7.8% of participants achieved the cLDL target of less than 100 mg/dl (9.8% in men and 6.4% in women). Less than half of the participants (45.7%) achieved the systolic blood pressure (SBP) target of less than 130 mmHg and diastolic blood pressure (DBP) target of less than 80 mmHg (51.0% in men and 42.3% in women), and 31.8% had hypertensive blood pressure values (SBP>140mmHg or DBP>90mmHg). Only 1.6% of adults with diabetes attained the recommended goals of HbA1c level lower than 7.0%, cLDL lower than 100mg/dl, and blood pressure lower than 130/80mmHg.

Conclusions

Further public health efforts are needed to control risk factors for vascular disease among individuals with diagnosed diabetes.

Key words:
Diabetes
Target goals
HbA1c
cLDL
Blood pressure
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.I. Harris.
Summary.
National Diabetes Data Group, editor. Diabetes in America, 2nd ed., National Institute of Diabetes and Digestive and Kidney Disease, (1995),
[2.]
American Diabetes Association.
Economic consequences of diabetes mellitus in the US in 2002.
Diabetes Care, 26 (2003), pp. 917-932
[3.]
R. Klein, B.E.K. Klein.
Vision disorders in diabetes.
National Diabetes Data Group, editor. Diabetes in America, 2nd ed., National Institute of Diabetes and Digestive and Kidney Disease, (1995),
[4.]
R. Klein.
Hyperglycemia and microvascular and macrovascular disease in diabetes.
Diabetes Care, 18 (1995), pp. 258-268
[5.]
R.C. Eastman.
Neuropathy in diabetes.
National Diabetes Data Group, editor. Diabetes in America, 2nd ed., National Institute of Diabetes and Digestive and Kidney Disease, (1995),
[6.]
D. Wingard, E. Barrett-Connor.
Heart disease and diabetes.
National Diabetes Data Group, editor. Diabetes in America, 2nd ed., National Institute of Diabetes and Digestive and Kidney Disease, (1995),
[7.]
I.M. Stratton, A.I. Adler, H.A. Neil, D.R. Matthews, S.E. Manley, C.A. Cull, et al.
Association of glycaemia and macrovascular and microvascular complications in type 2 diabetes (UKPDS 35): prospective observational study.
BMJ, 321 (2000), pp. 405-412
[8.]
Diabetes Control and Complications Trial Research Group.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
N Engl J Med, 329 (1993), pp. 977-986
[9.]
UK Prospective Diabetes Study Group.
Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet, 352 (1998), pp. 837-853
[10.]
M. Wei, S.P. Gaskill, S.M. Haffner, M.P. Stern.
Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality: the San Antonio Heart Study.
Diabetes Care, 21 (1998), pp. 1167-1172
[11.]
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.
JAMA, 287 (2002), pp. 2563-2569
[12.]
Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Research Group.
Intensive diabetes terapy and carotid intima-media thickness in type 1 diabetes mellitus.
N Engl J Med, 348 (2003), pp. 2294-2303
[13.]
UK Prospective Diabetes Study (UKPDS) Group.
Tight blood pressure control and risk of macrovascular and microvascular complication in type 2 diabetes: UKPDS 38.
BMJ, 317 (1998), pp. 703-713
[14.]
I. Hansson, A. Zanchetti, S.G. Carruthers, B. Dahlof, D. Elmfeldt, S. Julius, et al.
Effects of intensive blood-presure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group.
Lancet, 351 (1998), pp. 1755-1762
[15.]
K. Pyorala, T.R. Pedersen, J. Kjekshus, O. Faergeman, A.G. Olsson, G. Thorgeirsson, et al.
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).
Diabetes Care, 20 (1997), pp. 614-620
[16.]
P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, O. Pedersen, et al.
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
N Engl J Med, 348 (2003), pp. 383-393
[17.]
CDC Diabetes Cost-effectiveness Group.
Cost-effectiviness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
JAMA, 287 (2002), pp. 2542-2551
[18.]
American Diabetes Association.
Standards of medical care for patients with diabetes mellitus.
Diabetes Care, 26 (2003), pp. S33-S50
[19.]
A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo, The National High Blood Pressure Education Program Coordinating Committee, et al.
The seventh report of the National Joint Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC VII Report.
JAMA, 289 (2003), pp. 2560-2572
[20.]
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
Executive summary of the Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III).
JAMA, 289 (2001), pp. 2486-2497
[21.]
S.M. Grundy, J.I. Cleeman, C.N. Bairey Merz, H.B. Brewer, L.T. Clark, D.B. Hunninghake, The Coordinating Committee of the National Cholesterol Education Program, et al.
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Circulation, 110 (2004), pp. 227-239
[22.]
S.H. Saydah, J. Fradkin, C.C. Cowie.
Poor control of risk factor for vascular disease among adults with previously diagnosed diabetes.
JAMA, 291 (2004), pp. 335-342
[23.]
National Center for Health Statistics. NHANES 1999-2000 data files; 2002 [citado 14 de octubre de 2002]. Disponible en: http://www.cdc.gov/nchs/about/major/nhanes/NHANES99_00.htm
[24.]
National Center for Health Statistics.
Analytic and Reporting Guidelines: The Third National Health and Nutrition Examination Survey. NHANES III (1988-1994).
US Dept of Health and Human Services, (1997),
[25.]
C.M. Clark, J.E. Fradkin, R.G. Hiss, R.A. Lorenz, F. Vinicor, E. Warren-Boulton, et al.
The National Diabetes Education Program Changing the way diabetes is treated.
Diabetes Care, 24 (2001), pp. 617-618
[26.]
S.E. Inzucchi.
Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
JAMA, 287 (2002), pp. 360-372
[27.]
A. Liebl, A. Spannheimer, U. Reitberger, A. Gortz.
Costs of longterm complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study.
Med Klin, 97 (2002), pp. 713-719
[28.]
Sociedad Ecuatoriana de Endocrinología.
Consenso Ecuatoriano sobre el Diagnóstico y Manejo de Diabetes Mellitus Tipo 2. 2003.
SEE, (2003),
[29.]
T.M.E. Davis, S. Colagiuri.
The continuing legacy of the United Kingdom Prospective Diabetes Study.
Med J Aust, 180 (2004), pp. 104-105
[30.]
S.M. Haffner, S. Lehto, T. Rönnemaa, K. Pyörala, M. Laakso.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med, 339 (1998), pp. 229-234
[31.]
R.B. Golberg, H.J. Mellies, F.M. Sacks, L.A. Moye, B.V. Howard, W.J. Howard, for the CARE Investigators, et al.
Cardiovascular events and their reduction with pravastatin in diabetic and glucose- intolerant myocardial infarction survival with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial.
Circulation, 98 (1998), pp. 2513-2519
[32.]
H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, M.B. Elam, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, et al.
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.
N Engl J Med, 341 (1999), pp. 410-418
[33.]
American Diabetes Association.
Dyslipidemia management in adults with Diabetes.
Diabetes Care, 27 (2004), pp. S68-S71
Copyright © 2006. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos